In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins

Biochemical Pharmacology

Volumn 68, Issue 12, 2004, Pages 2409-2416

  Fröhlich, Margit ^a   Albermann, Nadine ^a   Sauer, Alexandra ^a   Walter Sack, Ingeborg ^a   Haefeli, Walter E ^a   Weiss, Johanna ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Calcein assay; Hormone replacement therapy; Inhibition; Oral contraceptives; P glycoprotein; Progestins

Indexed keywords

ANTIINFECTIVE AGENT; CALCEIN; CHLORMADINONE; CYPROTERONE; DESOGESTREL; GESTAGEN; GLYCOPROTEIN P; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; NORGESTIMATE; PROGESTERONE; PROTEINASE INHIBITOR; QUINIDINE; RHODAMINE 123;

ARTICLE; CELL LINE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ASSAY; FLUORESCENCE; GENDER; HORMONE BLOOD LEVEL; HUMAN; IN VITRO STUDY; MEASUREMENT; ORAL CONTRACEPTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELLS, CULTURED; FEMALE; FLUORESCEINS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; P-GLYCOPROTEIN; PROGESTERONE; PROGESTINS; SEX CHARACTERISTICS;

EID: 8844275880     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.08.026     Document Type: Article

References (46)

1. S.V. Ambudkar, S. Dey, C.A. Hrycynas, M. Ramachandrda, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
2. M.M. Gottesman, and I. Pastan Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 62 1993 385 427
3. R.Z. Harris, L.Z. Benet, and J.B. Schwartz Gender effects in pharmacokinetics and pharmacodynamics Drugs 50 1995 222 239
4. C.L. Cummins, C.-Y. Wu, and L.Z. Benet Sex-related differences in the clearance of cytochrome P4503A4 substrates may be caused by P-glycoprotein Clin. Pharmacol. Ther. 72 2002 474 489
5. K. Ueda, C. Cardarelli, M.M. Gottesman, and I. Pastan Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine Proc. Natl. Acad. Sci. USA 84 1987 3004 3008
6. C. Zibera, N. Gibelli, L. Maestri, and G.R. Della Cuna Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line Anticancer. Res. 15 1995 745 749
7. G.F. Fleming, J.M. Amato, M. Agresti, and A.R. Safa Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein Cancer Chemother. Pharmacol. 29 1992 445 449
8. H. Steiner, A. Polliack, C. Kimichi-Sarafaty, D. Libster, E. Fibach, and D. Rund Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukaemia suggest possible gender and stage variations in drug-resistance gene activity Ann. Hematol. 76 1998 189 194
9. D. Catovsky, J. Fooks, and S. Richards Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC working party on leukaemia in adults Br. J. Haematol. 72 1989 141 149
10. C.-H. Yang, S.G. de Phino, L.M. Greenberger, R.J. Arceci, and S.B. Horwitz Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus J. Biol. Chem. 264 1989 282 288
11. K.M. Barnes, B. Dickstein, G.B. Cutler, T. Fojo, and S.E. Bates Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells Biochemistry 35 1996 4820 4827
12. K.O. Hamilton, M.A. Yazdanian, and K.L. Audus Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands Int. J. Pharm. 228 2001 171 179
13. K. Heinemann, S. Moehner, M. Lewis, A. Assmann, E. Garbe, and L.A. Heinemann Trends of OC use 1980-1999 in a German cohort of women Zentralbl. Gynäkol. 124 2002 128 131
14. C. Thiel, L.A. Heinemann, and A. Assmann German cohort study on women's health. Reasons for the change in HRT therapy from the perspective of women. Results of the German cohort study on women's health Zentralbl. Gynäkol. 123 2001 390 398
15. A.H. Schinkel, E. Wagenaar, C.A. Mol, and L. van Deemter P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J. Clin. Invest. 1996 2517 2524
16. J. Weiss, S.G. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash, and W.E. Haefeli Inhibition of P-glycoprotein by newer antidepressants J. Pharmacol. Exp. Ther. 305 2003 197 204
17. D. Boesch, C. Gaveriaux, B. Jachez, A. Pourtier-Manzane-Do, P. Bollinger, and F. Loor In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833 Cancer Res. 51 1991 4226 4233
18. M. Hitzl, S. Drescher, H. van der Kuip, E. Schaffeler, J. Fischer, and M. Schwab The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells Pharmacogenetics 11 2001 293 298
19. A. Stewart, J. Steiner, G. Mellows, B. Laguda, D. Norris, and P. Bevan Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration Clin. Cancer Res. 6 2000 4186 4191
20. S.M. Witherspoon, D.L. Emerson, B.M. Kerr, T.L. Llyod, W.S. Dalton, and P.S. Wissel Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918 Clin. Cancer Res. 2 1996 7 12
21. N. Feller, C.M. Kuiper, J. Lankelma, J.K. Ruhdal, R.J. Scheper, and H.M. Pinedo Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry Br. J. Cancer. 72 1995 543 549
22. A.H. Dantzig, R.L. Shepard, K.L. Law, L. Tabas, S. Pratt, and J.S. Gillespie Selectivity of the multidrug resistance modulator LY335979, P-glycoprotein and effect on cytochrome P-450 activities J. Pharmacol. Exp. Ther. 290 1999 854 862
23. P.M. Chaudhary, E.B. Mechetner, and I.B. Roninson Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes Blood 81 1992 3480 3481
24. C. Trambas, Z. Wang, M. Cianfrigila, and G. Woods Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein Br. J. Haematol. 114 2001 177 184
25. D. Schwab, H. Fischer, A. Tabatabei, S. Poli, and J. Huwyler Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery J. Med. Chem. 46 2003 1716 1725
26. E. Crivellato, L. Candussio, A.M. Rosati, F. Batoli-Klugmann, F. Maliardi, and G. Decorti The fluorescent probe bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance protein (MRP)-1 J. Histochem. Cytochem. 50 2002 731 734
27. J. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, and D.D. Ross The multidrug-resistant phenotype associated with over-expression of the new ABC half-transporter, MXR (ABCG2) Cell Sci. 113 2000 2011 2021
28. E.J. Wang, C.M. Casciano, R.P. Clement, and W.W. Johnson In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein Drug Metab. Dispos. 28 2000 522 528
29. M. Verschraagen, C.H. Koks, J.H. Schellens, and J.H. Beijnen P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharmacol. Res. 40 1999 301 306
30. M.F. Fromm, R.B. Kim, C.M. Stein, G.R. Wilkinson, and D.M. Roden Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 1999 552 557
31. H.O. Klein, R. Lang, E. Weiss, E. Di Segni, C. Libhaber, and J. Guerriero The influence of verapamil on serum digoxin concentration Circulation 6 1982 998 1003
32. E.B. Leahey, J.A. Reiffel, E.G. Giardina, and J.T. Bigger Jr The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study Ann. Intern. Med. 92 1980 605 608
33. H. Kuhl Comparative pharmacology of newer progestogens Drugs 51 1996 188 215
34. U. Speck, H. Wendt, P.E. Schulze, and D. Jentsch Bio-availability and pharmacokinetics of cyproterone acetate and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB) Contraception 14 1976 151 163
35. A. Nakayama, O. Eguchi, M. Hatakeyama, H. Saitoh, and M. Takada Different absorption behaviors among steroid hormones due to possible interaction with P-glycoprotein in the rat small intestine Biol. Pharm. Bull. 22 1999 535 538
36. O. Turriziani, G. Antonelli, and F. Dianzani Cellular factors involved in the induction of resistance of HIV to antiretroviral agents Int. J. Antimicrob. Agents 16 2000 353 356
37. K. Jones, P.G. Hoggard, S.D. Sales, S. Khoo, R. Davey, and D.J. Back Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport AIDS 15 2001 675 681
38. E.R. Meaden, P.G. Hoggard, P. Newton, J.F. Tija, D. Aldam, and D. Cornforth P-glycoprotein and PRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals J. Antimicrob. Chemother. 50 2002 583 588
39. K. Jones, P.G. Bray, S.H. Khoo, R.A. Davey, E.R. Meaden, and S.A. Ward P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug-resistance? AIDS 15 2001 1352 1358
40. R.A. Clark, and R. Bessinger Clinical manifestations and predictors of survival in older woman infected with HIV J. Aquir. Immune. Defic. Syndr. 15 1997 341 345
41. M. Fröhlich, J. Burhenne, M. Martin-Facklam, J. Weiss, M. von Wolff, and T. Strowitzky Oral contraception does not alter single dose saquinavir pharmacokinetics in women Br. J. Clin. Pharmacol. 57 2004 244 252
42. S.S. Rathore, Y. Wang, and H.M. Krumholz Sex-based differences in the effect of digoxin for the treatment of heart failure N. Engl. J. Med. 347 2002 1403 1411
43. B. Meibohm, I. Beierle, and H. Derendorf How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41 2002 329 342
44. G.M. Shenfield, and J.M. Griffin Clinical pharmacokinetics of contraceptive steroids. An update Clin. Pharmacokinet. 20 1991 15 37
45. M. Ehrhardt, H. Lindenmaier, J. Burhenne, W.E. Haefeli, and J. Weiss Influence of lipid lowering fibrates on P-glycoprotein activity in vitro Biochem. Pharmacol. 67 2004 285 292
46. N. Ketabi-Kiyanvash, J. Weiss, W.E. Haefeli, and G. Mikus P-glycoprotein modulation by the designer drugs methylendioxymethamphetamine, methylenedioxyethylamphetamine, and paramethoxyamphetamine Addict. Biol. 8 2003 413 418